RASD2
GTP-binding protein Rhes
Also known as: MGC:4834, Rhes, RHES_HUMAN, TEM2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96D21
- Gene
- RASD2
- Ensembl
- ENSG00000100302
- Chromosome
- 22
- Canonical length
- 266 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Plasma membrane,Cytosol
OverviewNCBI Gene
This gene belongs to the Ras superfamily of small GTPases and is enriched in the striatum. The encoded protein functions as an E3 ligase for attachment of small ubiquitin-like modifier (SUMO). This protein also binds to mutant huntingtin (mHtt), the protein mutated in Huntington disease (HD). Sumoylation of mHTT by this protein may cause degeneration of the striatum. The protein functions as an activator of mechanistic target of rapamycin 1 (mTOR1), which in turn plays a role in myelination, axon growth and regeneration. Reduced levels of mRNA expressed by this gene were found in HD patients. [provided by RefSeq, Jan 2016]
Canonical amino-acid sequenceUniProt
266 residues, UniProt reviewed canonical sequence.
>Q96D21|RASD2
1 MMKTLSSGNC TLSVPAKNSY RMVVLGASRV GKSSIVSRFL NGRFEDQYTP TIEDFHRKVY
61 NIRGDMYQLD ILDTSGNHPF PAMRRLSILT GDVFILVFSL DNRESFDEVK RLQKQILEVK
121 SCLKNKTKEA AELPMVICGN KNDHGELCRQ VPTTEAELLV SGDENCAYFE VSAKKNTNVD
181 EMFYVLFSMA KLPHEMSPAL HRKISVQYGD AFHPRPFCMR RVKEMDAYGM VSPFARRPSV
241 NSDLKYIKAK VLREGQARER DKCTIQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RASD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 184 nTPM
Expression across tissuesHPA
Tissue
- basal ganglia: 184 nTPM
- cerebral cortex: 33 nTPM
- colon: 26 nTPM
- seminal vesicle: 21 nTPM
- amygdala: 15 nTPM
- prostate: 15 nTPM
Single-cell type
- adrenal medulla cells: 32 nCPM
- pericytes: 30 nCPM
- brain inhibitory neurons: 29 nCPM
- epididymal principal cells: 21 nCPM
- goblet cells: 15 nCPM
- epididymal clear cells: 12 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 465 nTPM
- thalamus: 121 nTPM
- amygdala: 84 nTPM
- cerebral cortex: 83 nTPM
- midbrain: 45 nTPM
- hippocampal formation: 40 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.74
- gnomAD pLI
- 0.54
- gnomAD missense Z
- 1.69
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- locomotory behavior
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of protein sumoylation
- signal transduction
- synaptic transmission, dopaminergic
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RASD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RASD2 as an antibody target. Whether an autoantibody or antibody against RASD2 could matter depends on whether native RASD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RASD2 is annotated at the cell surface, where native RASD2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label RASD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...